MDS – Medxy AI

Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCT

By MedXY 06/30/2026

Fludarabine, cyclophosphamide, and low-dose TBI combined with post-transplant cyclophosphamide provide a safe and effective single platform for haploidentical and unrelated donor allo-SCT in older AML/MDS patients, showing favorable survival and GVHD outcomes.

Hematology-Oncology news Oncology

Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS

By MedXY 06/02/2026

A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and encouraging early survival outcomes.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

TP53 Multihit Does Not Fully Erase the Prognostic Advantage of Isolated del(5q) in Myelodysplastic Neoplasms

By MedXY 05/09/2026

A multicenter retrospective study suggests that MDS with isolated del(5q) and TP53 multihit alterations has substantially better survival than other low-blast TP53-multihit MDS, challenging how this subgroup should be classified.

$Rogocekib Demonstrates Clinical Activity as a First-in-Class CLK Inhibitor in Relapsed or Refractory AML and MDS$

Hematology-Oncology news

Rogocekib Demonstrates Clinical Activity as a First-in-Class CLK Inhibitor in Relapsed or Refractory AML and MDS

By MedXY 01/19/2026

This Phase 1 study evaluates rogocekib, a novel CDC2-like kinase inhibitor, in patients with relapsed or refractory hematologic malignancies, reporting manageable safety and significant complete remission rates in AML and MDS cohorts, signaling a new frontier in splicing-targeted therapy.